Biosyent Inc V.RX

Alternate Symbol(s): BIOYF

Healthcare

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.

TSXV:RX - Post by User

Biosyent Inc > Expect a Dividend from BioSyent Next Year

<< Previous

Bullboard Posts

Next >>

Post by ZakDixonon Nov 19, 2021 12:12pm

257 Views

Post# 34146148

Expect a Dividend from BioSyent Next Year

BioSyent Management is averse to promoting its own share price. It does not give future guidance and won't say anything positive about the share although it may be considering. The CEO, Rene Goehrum in his presentation on the 3rd quarter vaguely said "If we have capital that we believe is in excess of our strategy, we will turn that to shareholders. The obvious way to do that is dividends and share buybacks..". Given that the share buybacks have reduced to a trickle and that the float is not large, the 'obvious' way is now dividends. Expect a maiden dividend next year.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023